240 related articles for article (PubMed ID: 15381637)
21. Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation.
Singh G; Maguire JJ; Kuc RE; Skepper JN; Fidock M; Davenport AP
Br J Pharmacol; 2006 Dec; 149(7):838-44. PubMed ID: 17043672
[TBL] [Abstract][Full Text] [Related]
22. Corticotropin-releasing factor (CRF) and the urocortins differentially regulate catecholamine secretion in human and rat adrenals, in a CRF receptor type-specific manner.
Dermitzaki E; Tsatsanis C; Minas V; Chatzaki E; Charalampopoulos I; Venihaki M; Androulidaki A; Lambropoulou M; Spiess J; Michalodimitrakis E; Gravanis A; Margioris AN
Endocrinology; 2007 Apr; 148(4):1524-38. PubMed ID: 17194738
[TBL] [Abstract][Full Text] [Related]
23. Three-amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity.
Jahn O; Tezval H; van Werven L; Eckart K; Spiess J
Neuropharmacology; 2004 Aug; 47(2):233-42. PubMed ID: 15223302
[TBL] [Abstract][Full Text] [Related]
24. Corticotropin-releasing factor receptors and urocortins, links between the brain and the heart.
Yang LZ; Tovote P; Rayner M; Kockskämper J; Pieske B; Spiess J
Eur J Pharmacol; 2010 Apr; 632(1-3):1-6. PubMed ID: 20132811
[TBL] [Abstract][Full Text] [Related]
25. The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain.
Lawrence AJ; Krstew EV; Dautzenberg FM; Rühmann A
Br J Pharmacol; 2002 Jul; 136(6):896-904. PubMed ID: 12110614
[TBL] [Abstract][Full Text] [Related]
26. Corticotropin-releasing factor receptor 1 and central heart rate regulation in mice during expression of conditioned fear.
Stiedl O; Meyer M; Jahn O; Ogren SO; Spiess J
J Pharmacol Exp Ther; 2005 Mar; 312(3):905-16. PubMed ID: 15537825
[TBL] [Abstract][Full Text] [Related]
27. Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity.
Zorrilla EP; Reinhardt LE; Valdez GR; Inoue K; Rivier JE; Vale WW; Koob GF
J Pharmacol Exp Ther; 2004 Sep; 310(3):1027-34. PubMed ID: 15115804
[TBL] [Abstract][Full Text] [Related]
28. Urocortin 1, urocortin 3/stresscopin, and corticotropin-releasing factor receptors in human adrenal and its disorders.
Fukuda T; Takahashi K; Suzuki T; Saruta M; Watanabe M; Nakata T; Sasano H
J Clin Endocrinol Metab; 2005 Aug; 90(8):4671-8. PubMed ID: 15914529
[TBL] [Abstract][Full Text] [Related]
29. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.
Dautzenberg FM; Py-Lang G; Higelin J; Fischer C; Wright MB; Huber G
J Pharmacol Exp Ther; 2001 Jan; 296(1):113-20. PubMed ID: 11123370
[TBL] [Abstract][Full Text] [Related]
30. Functional CRF receptors in BON cells stimulate serotonin release.
von Mentzer B; Murata Y; Ahlstedt I; Lindström E; Martínez V
Biochem Pharmacol; 2007 Mar; 73(6):805-13. PubMed ID: 17184738
[TBL] [Abstract][Full Text] [Related]
31. Urocortins and the regulation of gastrointestinal motor function and visceral pain.
Martinez V; Wang L; Million M; Rivier J; Taché Y
Peptides; 2004 Oct; 25(10):1733-44. PubMed ID: 15476940
[TBL] [Abstract][Full Text] [Related]
32. Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.
Beyermann M; Heinrich N; Fechner K; Furkert J; Zhang W; Kraetke O; Bienert M; Berger H
Br J Pharmacol; 2007 Jul; 151(6):851-9. PubMed ID: 17533422
[TBL] [Abstract][Full Text] [Related]
33. Corticotropin-releasing factor, urocortin 1, and their receptors in the mouse spinal cord.
Korosi A; Kozicz T; Richter J; Veening JG; Olivier B; Roubos EW
J Comp Neurol; 2007 Jun; 502(6):973-89. PubMed ID: 17444496
[TBL] [Abstract][Full Text] [Related]
34. Evidence supporting a role for corticotropin-releasing factor type 2 (CRF2) receptors in the regulation of subpopulations of serotonergic neurons.
Staub DR; Evans AK; Lowry CA
Brain Res; 2006 Jan; 1070(1):77-89. PubMed ID: 16403469
[TBL] [Abstract][Full Text] [Related]
35. Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2.
Tsatsanis C; Androulidaki A; Dermitzaki E; Gravanis A; Margioris AN
J Cell Physiol; 2007 Mar; 210(3):774-83. PubMed ID: 17117478
[TBL] [Abstract][Full Text] [Related]
36. Labelling of CRF1 and CRF2 receptors using the novel radioligand, [3H]-urocortin.
Gottowik J; Goetschy V; Henriot S; Kitas E; Fluhman B; Clerc RG; Moreau JL; Monsma FJ; Kilpatrick GJ
Neuropharmacology; 1997 Oct; 36(10):1439-46. PubMed ID: 9423932
[TBL] [Abstract][Full Text] [Related]
37. Vasodilative effects of urocortin II via protein kinase A and a mitogen-activated protein kinase in rat thoracic aorta.
Kageyama K; Furukawa K; Miki I; Terui K; Motomura S; Suda T
J Cardiovasc Pharmacol; 2003 Oct; 42(4):561-5. PubMed ID: 14508243
[TBL] [Abstract][Full Text] [Related]
38. The roles of corticotropin-releasing factor-related peptides and their receptors in the cardiovascular system.
Nazarloo HP; Buttrick PM; Saadat H; Dunn AJ
Curr Protein Pept Sci; 2006 Jun; 7(3):229-39. PubMed ID: 16787262
[TBL] [Abstract][Full Text] [Related]
39. Influence of urocortin and corticotropin releasing factor on venous tone in conscious rats.
Abdelrahman AM; Lin Lim S; Pang CC
Eur J Pharmacol; 2005 Mar; 510(1-2):107-11. PubMed ID: 15740730
[TBL] [Abstract][Full Text] [Related]
40. The effects of CRF and the urocortins on [3H]GABA release from the rat amygdala--an in vitro superfusion study.
Bagosi Z; Jászberényi M; Szabó G; Telegdy G
Brain Res Bull; 2008 Jan; 75(1):15-7. PubMed ID: 18158090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
